Sudan Loganathan Analyst Performance

Managing Director at Stephens

Sudan Loganathan is a stock analyst at Stephens in the medical sector, covering 8 publicly traded companies. Over the past year, Sudan Loganathan has issued 13 stock ratings, including buy and hold recommendations. While full access to Sudan Loganathan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sudan Loganathan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 13 Last 0 Years
Buy Recommendations: 69.23% 9 Buy Ratings
Companies Covered: 8 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	69.2%	9 ratings
Hold	30.8%	4 ratings
Sell	0.0%	0 ratings

Out of 13 total stock ratings issued by Sudan Loganathan at Stephens, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	8 companies

Sudan Loganathan, an analyst at Stephens, currently covers 8 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 8 companies	100.0%

Sudan Loganathan of Stephens specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	87.5%
MED INSTRUMENTS 1 company	12.5%

About Sudan Loganathan

Sudan Loganathan, PhD is a Managing Director and equity research analyst covering the Biotechnology sector, with a focus on oncology, immunology and rare diseases. Sudan joined Stephens in May 2023, following previous roles as an equity research associate or senior associate at Cantor Fitzgerald, H.C. Wainwright and RBC Capital Markets following large-cap pharma, specialty pharma and biotechnology sectors. Sudan received his B.S. in Biomedical Sciences from Murray State University in 2013 and his Ph.D. from Meharry Medical College and Vanderbilt University Medical Center in Neuroscience, Cancer Biology and Pharmacology in 2018.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CCCC C4 Therapeutics	9/22/2025	Reiterated Rating	$3.16	$6.00	Overweight
ARVN Arvinas	9/18/2025	Lower Price Target	$7.61	$14.00	Overweight
CCCC C4 Therapeutics	9/15/2025	Upgrade	$2.66	$6.00	Overweight
IDYA IDEAYA Biosciences	9/9/2025	Reiterated Rating	$23.39	$45.00	Overweight
NRIX Nurix Therapeutics	7/10/2025	Reiterated Rating	$13.18	$30.00	Overweight
EXEL Exelixis	6/24/2025	Upgrade	$43.37	$60.00	Overweight
DCTH Delcath Systems	6/23/2025	Reiterated Rating	$13.47	$25.00	Overweight
BPMC Blueprint Medicines	6/3/2025	Downgrade	$127.79	$135.00	Hold
ELEV Elevation Oncology	3/24/2025	Reiterated Rating	$0.30	$1.00	Equal Weight
ELEV Elevation Oncology	3/7/2025	Reiterated Rating	$0.51	$5.00	Overweight
EXEL Exelixis	2/12/2025	Reiterated Rating	$35.11	$29.00	Equal Weight
EXEL Exelixis	1/27/2025	Reiterated Rating	$33.37	$29.00	Equal Weight
NRIX Nurix Therapeutics	1/21/2025	Reiterated Rating	$19.84	$31.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.